Similar to 2017 and 2018, the US FDA in 2019 approved an increasing number of orphan drugs and biologics, as well as drugs targeted at specific cancers. Sponsors have continued to target the development of pricier orphan treatments and the Center for Drug Evaluation and Research (CDER) reported approving more than twice as many orphan drugs in the past eight years as in the previous eight years. In addition, more than one-third of CDER’s novel drug approvals in 2019 were cancer treatments. Learn More